BNTXBioNTech SE

Nasdaq biontech.de


$ 96.87 $ -2.05 (-2.07 %)    

Friday, 24-May-2024 15:59:54 EDT
QQQ $ 454.82 $ 4.29 (0.95 %)
DIA $ 398.57 $ -0.02 (-0.01 %)
SPY $ 530.36 $ 3.48 (0.66 %)
TLT $ 91.26 $ 0.27 (0.3 %)
GLD $ 225.37 $ 0.20 (0.09 %)
$ 96.95
$ 98.37
$ 0.00 x 0
$ 0.00 x 0
$ 94.56 - $ 98.86
$ 85.21 - $ 125.83
1,245,252
na
23.05M
$ 0.08
$ 0.02
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 moderna-was-among-the-best-performing-large-cap-stocks-last-week-may-20-may-26-2024-are-they-in-your-portfolio

Top-performing stocks last week were FSLR, MRNA, ELF, NVDA, IP, ADI, FLEX, LOGI, BNTX, and MNDY, boosted by positive news and a...

 hc-wainwright--co-reiterates-buy-on-biontech-maintains-113-price-target

HC Wainwright & Co. analyst Robert Burns reiterates BioNTech (NASDAQ:BNTX) with a Buy and maintains $113 price target.

 experts-predict-rise-in-covid-19-cases-vaccine-stocks-climb

Experts predict a small rise in COVID-19 cases as a newly dominant strain spreads. The new strain, KP.2, represents 28% of Covi...

Core News & Articles

https://www.nbcnews.com/now/video/disease-experts-predict-a-small-rise-in-covid-cases-this-summer-211393605953 Disease experts ...

 biontech-says-european-patent-offices-decision-to-maintain-modernas-patent-ep-no-3-590-949-b1-in-amended-form-does-not-change-cos-stance-on-patent-says-believe-that-neither-ep-949-nor-any-of-the-auxiliary-requests-filed-by-moderna-meet-the-requirements-for-patentability-says-will-continue-to-vigorously-defend-its-innovations-against-all-allegations-of-patent-infringement-including-ep-949-case

-Reuters

 european-patent-office-sides-with-moderna-in-covid-19-vaccine-patent-dispute-with-pfizerbiontech

Moderna wins a crucial legal battle at the European Patent Office against Pfizer and BioNTech over Covid-19 vaccine patents.

Core News & Articles

https://www.ft.com/content/50c5078c-c9f0-4b35-b916-3475b641c773Moderna has won a case at the European Patent Office in its disp...

 evercore-isi-group-initiates-coverage-on-biontech-with-in-line-rating-announces-price-target-of-100

Evercore ISI Group analyst Cory Kasimov initiates coverage on BioNTech (NASDAQ:BNTX) with a In-Line rating and announces Pri...

 elon-musk-breaks-ranks-with-gop-by-praising-genetic-engineering-tech-that-helped-fight-covid-19-digital-medicine-with-incredible-potential

Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists.

 hc-wainwright--co-maintains-buy-on-biontech-raises-price-target-to-113

HC Wainwright & Co. analyst Robert Burns maintains BioNTech (NASDAQ:BNTX) with a Buy and raises the price target from $1...

 td-cowen-maintains-hold-on-biontech-raises-price-target-to-98

TD Cowen analyst Yaron Werber maintains BioNTech (NASDAQ:BNTX) with a Hold and raises the price target from $95 to $98.

 bmo-capital-maintains-outperform-on-biontech-lowers-price-target-to-122

BMO Capital analyst Etzer Darout maintains BioNTech (NASDAQ:BNTX) with a Outperform and lowers the price target from $123 to...

 whats-going-with-biontech-stock-on-monday

BioNTech reports Q1 loss, missing revenue expectations. Despite challenges, BioNTech aims for significant growth, fueled by inn...

 wall-street-looks-to-extend-rally-amid-caution-over-fed-speeches-more-earnings-why-this-analyst-thinks-bull-market-is-still-quite-young

U.S. stocks are likely to extend their gains as major index futures are modestly higher on Monday. Strong earnings reports cont...

 biontech-reaffirms-2024-revenue-guidance-of-25b-31b

Planned 2024 Financial Year Expenses and Capex R&D expenses: €2.4B-€2.6B SG&A expenses: €700M-€800M Capital expend...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION